Dewpoint Therapeutics is a biotech company developing a drug platform that targets biomolecular condensates.
Dewpoint Therapeutics has raised $59.1M in total funding. The most recent round was Series D. The last funding was announced in September 2025.
Dewpoint Therapeutics's investors include General Catalyst, Maverick Ventures, ARCH Venture Partners, Samsara BioCapital, SoftBank Vision Fund.
Dewpoint Therapeutics is headquartered in Boston, United States.
Dewpoint Therapeutics is a biotech company developing a drug platform that targets biomolecular condensates.
Dewpoint Therapeutics is at the Series D stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Dewpoint Therapeutics — Funding & Investors." VCBacked, September 10, 2025, https://www.vcbacked.co/company/dewpoint-therapeutics. Accessed July 19, 2026.
VCBacked. (2025). Dewpoint Therapeutics — Funding & Investors. Retrieved July 19, 2026, from https://www.vcbacked.co/company/dewpoint-therapeutics
{{cite web |title=Dewpoint Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/dewpoint-therapeutics |website=VCBacked |access-date=July 19, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated